Integra Lifesciences Holdings (IART)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$16.72+1.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · IART
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -35.9% |
| Our one-year growth estimate | diamond | 3.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 39.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers
IART — CEO transition
Dated 2026-05-05
President and Chief Executive Officer — Dr. Stuart M. Essig: Dr. Stuart Essig was appointed as President and Chief Executive Officer, succeeding Mojdeh Poul.
Why it matters: An EPS update will indicate how well the company is managing costs and profits.
Supportive ifEPS guidance raised above $1.00 for 2026.
Worry ifEPS guidance lowered below $0.80 for 2026.
Why it matters: A clear plan from the new CEO could help calm investors after the change.
Supportive ifA press release detailing a new strategic plan or vision for the company.
Worry ifNo announcement or vague statements about future direction from the new CEO.
Why it matters: A higher adjusted EBITDA margin means the company is more efficient. This leads to more profit.
Supportive ifAdjusted EBITDA margin goes above 19.4% in Q2 2026.
Worry ifAdjusted EBITDA margin falls below 19.4% in Q2 2026.
Why it matters: The new CEO's plan will change the company's path and affect investor trust.
Watch forNew plans were announced that match growth goals.
Also watch forThere are no new plans or a delay in the strategy rollout.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$178 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $461 loss on $10,000 · 4.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,479 loss on $10,000 · 44.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This guidance shows confidence in making more money. It also helps improve operations.
Supportive ifManagement reaffirms adjusted EPS guidance within the range of $2.40 to $2.50.
Worry ifManagement lowers the adjusted EPS guidance to less than $2.40.
Why it matters: The relaunch is crucial for revenue growth in the tissue reconstruction segment. It shows the company's ability to innovate and meet market needs.
Supportive ifSuccessful relaunch of SurgiMend in Q4 2026 as planned.
Worry ifDelay in the relaunch of SurgiMend beyond Q4 2026.
Why it matters: This will help assess if the company can sustain growth momentum or if it is losing market share.
Worry ifQ1 2026 organic revenue growth is reported below 1.3%.
Less concerning ifQ1 2026 organic revenue growth is reported above 1.3%.
Why it matters: Stable or growing revenue means success in changes made.
Supportive ifQ1 2026 revenue growth stabilizes or improves above 1.3% year over year.
Worry ifQ1 2026 revenue growth declines below 1.3% year over year.
Why it matters: Revenue growth shows how well the company is bouncing back.
Watch forRevenue growth stays above 3% each year in the next reports.
Also watch forRevenue growth drops below 0% year over year.
Why it matters: Hitting this EPS target would show management cares about making more money.
Supportive ifQ3 adjusted EPS reported at or above $0.61.
Worry ifQ3 adjusted EPS reported below $0.53.
Why it matters: Better cash flow shows more efficiency. It also shows better financial health.
Supportive ifCash flow from operations exceeds $22.8 million in future quarters.
Worry ifCash flow from operations drops below $22.8 million.
Why it matters: The new CEO's clear goals can guide the company and boost investor trust.
Watch forThe new CEO presents a clear and actionable strategic plan during the earnings call.
Also watch forThe new CEO fails to provide a clear strategic plan during the earnings call.
Why it matters: Stuart Essig's return as CEO aims to strengthen execution and performance. This will show if the leadership change is effective.
Supportive ifCustomers liked the product. Key numbers got better in the next earnings call.
Worry ifThere may be ongoing operational issues or bad customer feedback in the next earnings call.
Why it matters: This guidance will show if the company can sustain its growth trajectory.
Watch forManagement expects revenue growth to be over 10% for 2026.
Also watch forManagement expects revenue growth to be under 5% for 2026.
Why it matters: This update will show if the company can meet its growth goals for 2026.
Supportive ifQ2 revenue guidance raised above 5% growth year over year.
Worry ifQ2 revenue guidance lowered below 0% growth year over year.
Why it matters: Meeting or exceeding this growth would confirm management's guidance and show strong demand.
Supportive ifQ3 reported revenue growth exceeds 5.7% year over year.
Worry ifQ3 reported revenue growth falls below 2.0% year over year.